2. Gene
  3. Ret - ret proto-oncogene Gene

Ret - ret proto-oncogene Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：ret 原癌基因

种属: Rattus norvegicus

基因 ID: 24716 | 基因类型: protein coding

关于 Ret

Primary_assembly 4: 151,326,431-151,368,176 reverse strand.mRatBN7.2:CM026977.1

This gene has 1 transcript (splice variant), 205 orthologues, 54 paralogues and is associated with 55 phenotypes. Biased expression in Brain (RPKM 34.7), Lung (RPKM 33.7) and 7 other tissues.

功能概要

预测该基因编码的蛋白编码的蛋白可启动钙离子结合活性和跨膜受体蛋白酪氨酸激酶活性。涉及多个过程，包括神经支配；神经元成熟的正向调节；和相机型眼睛的视网膜发育。位于多种细胞成分中，包括早期内体；膜筏；和神经细胞体。帕金森症的生物标志物；脑缺血;和嗜铬细胞瘤。该基因的人类直系同源物与先天性巨结肠有关；家族性甲状腺髓样癌；多发性内分泌肿瘤 2A 型；多发性内分泌肿瘤 2B 型；和嗜铬细胞瘤。与人类 RET（ret 原癌基因）同源。 [由基因组资源联盟提供，2022 年 4 月]

Predicted to enable calcium ion binding activity and transmembrane receptor protein tyrosine kinase activity. Involved in several processes, including innervation; positive regulation of neuron maturation; and retina development in camera-type eye. Located in several cellular components, including early endosome; membrane raft; and neuronal cell body. Biomarker of Parkinsonism; brain ischemia; and pheochromocytoma. Human ortholog(s) of this gene implicated in Hirschsprung's disease; familial medullary thyroid carcinoma; multiple endocrine neoplasia type 2A; multiple endocrine neoplasia type 2B; and pheochromocytoma. Orthologous to human RET (RET proto-oncogene). [provided by Alliance of Genome Resources, Apr 2022]

Ret 基因产物(2)

mRNA Protein Name
NM_001110099.1 NP_001103569.1 proto-oncogene tyrosine-protein kinase receptor Ret isoform b precursor
NM_012643.2 NP_036775.2 proto-oncogene tyrosine-protein kinase receptor Ret isoform a precursor
基因本体论
  • 生物过程
  • 细胞组分
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in innervation IMP
IMP: 通过突变表型推断
18501516 RGD
involved in positive regulation of neuron maturation IMP
IMP: 通过突变表型推断
18501516 RGD
involved in response to xenobiotic stimulus IEP
IEP: 通过表达模式推断
15837122 RGD
involved in retina development in camera-type eye IEP
IEP: 通过表达模式推断
16650834 RGD
细胞组分 GO 注释 逻辑证据 参考文献 来源
located in axon IDA
IDA: 通过直接分析推断
20877310 RGD
located in dendrite IDA
IDA: 通过直接分析推断
20877310 RGD
located in early endosome IDA
IDA: 通过直接分析推断
20877310 RGD
located in neuronal cell body IDA
IDA: 通过直接分析推断
20877310 RGD
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Ret 蛋白结构

RET_CLD1

RET_CLD1: pfam17756 (28 - 153)

Cadherin

Cadherin: pfam00028 (172 - 247)

RET_CLD3

RET_CLD3: pfam17812 (265 - 379)

RET_CLD4

RET_CLD4: pfam17813 (407 - 506)

PTKc_RET

PTKc_RET: cd05045 (723 - 1012)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1000
  • 1115 a.a.
蛋白主名 其他名称

proto-oncogene tyrosine-protein kinase receptor Ret

Ret gene for receptor tyrosin

Ret proto-oncogene (multiple endocrine neoplasia MEN2A MEN2B and medullary thyroid carcinoma 1 Hirschsprung disease)

receptor tyrosine kinase

相关产品

Approval
生物活性分子 (8)
目录号 产品名 作用方式
纯度 是否罕见病
HY-10981 Lenvatinib Inhibitor 99.75% 是
HY-10331 Regorafenib Inhibitor 99.93% 是
HY-114370 Selpercatinib Inhibitor 99.83% 是
HY-112301 Pralsetinib Inhibitor 99.98% 是
HY-10981A Lenvatinib mesylate Inhibitor 99.86% 是
HY-10331A Regorafenib monohydrate Inhibitor 99.96% 是
HY-13308 Regorafenib Hydrochloride Inhibitor 99.58% 是
HY-10331B Regorafenib mesylate Inhibitor / 否
Clinical Phase
生物活性分子 (6)
目录号 产品名 作用方式
纯度 Phase
HY-10206 Amuvatinib Inhibitor 99.47% Phase 2
HY-132846 Vepafestinib Inhibitor 98.61% Phase 2
HY-10206A Amuvatinib hydrochloride Inhibitor / Phase 2
HY-10032 PF 477736 Inhibitor 99.21% Phase 1
HY-100459 GSK3179106 Inhibitor 98.41% Phase 1
HY-149413 FHND5071 Inhibitor / Phase 1
Pre-clinical Phase
生物活性分子 (75)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-15002 AST 487 Inhibitor 99.42% 否
HY-10410 TG101209 Inhibitor 99.22% 否
HY-124401 BT-13 Agonist 99.57% 否
HY-101963 AD80 Inhibitor 99.88% 否
HY-18840 BBT594 Inhibitor 99.86% 否
HY-133551 WF-47-JS03 Inhibitor 99.63% 否
HY-156135 NSC194598 Inhibitor ≥98.0% 否
HY-110193 SPP-86 Inhibitor 99.62% 否
HY-145565 Enbezotinib Inhibitor 99.50% 否
HY-139590 Zeteletinib Inhibitor 99.06% 否
HY-153175 BT44 Activator 99.08% 否
HY-15769 WHI-P180 Inhibitor 99.62% 否
HY-U00437 Pz-1 Inhibitor 99.90% 否
HY-136534 RET V804M-IN-1 Inhibitor 98.22% 否
HY-101246 RPI-1 Inhibitor 99.29% 否
HY-112301A trans-Pralsetinib Inhibitor 96.07% 否
HY-10981S Lenvatinib-d4 Inhibitor 99.59% 否
HY-133553 RET-IN-3 Inhibitor 99.51% 否
HY-13342AS Apatinib-d8 free base 92.56% 否
HY-18317 JNJ-38158471 Inhibitor 97.02% 否
HY-10331S Regorafenib-d3 Inhibitor ≥98.0% 否
HY-18507 AD57 Inhibitor 98.08% 否
HY-34595 Pyrazoloadenine Inhibitor 99.98% 否
HY-132193 RET-IN-4 Inhibitor / 否
HY-139590A Zeteletinib hemiadipate Inhibitor / 否
HY-141896 RET-IN-7 Inhibitor 98.00% 否
HY-14979 ML786 Inhibitor / 否
HY-151987 RET-IN-20 Inhibitor / 否
HY-156113 RET-IN-25 Inhibitor / 否
HY-144422 RET-IN-15 Inhibitor / 否
HY-143545 RET-IN-8 Inhibitor / 否
HY-159967 LDD39 Degrader / 否
HY-145023 RET-IN-5 Inhibitor / 否
HY-149539 PLM-101 Inhibitor / 否
HY-14979A ML786 dihydrochloride Inhibitor / 否
HY-147563 RET-IN-17 Inhibitor / 否
HY-144131 RET-IN-11 Inhibitor / 否
HY-144029 RET-IN-13 Inhibitor / 否
HY-159824 Soxataltinib Inhibitor / 否
HY-151945 TRK II-IN-1 Inhibitor / 否
HY-161775 RET/TRKA-IN-1 Inhibitor / 否
HY-149099 RET-IN-22 Inhibitor / 否
HY-120214 TAS05567 / 否
HY-143546 RET-IN-9 Inhibitor / 否
HY-143615 RET-IN-10 Inhibitor / 否
HY-168105 RET-IN-27 Inhibitor / 否
HY-117873A KBP-7018 hydrochloride Inhibitor / 否
HY-156471 RET-IN-26 Inhibitor / 否
HY-164413 CLM3 Inhibitor / 否
HY-145024 RET-IN-6 Inhibitor / 否
HY-117873 KBP-7018 Inhibitor / 否
HY-151377 RET-IN-19 Inhibitor / 否
HY-18507A AD57 hydrochloride Inhibitor / 否
HY-10331S1 Regorafenib-13C,d3 Inhibitor / 否
HY-147564 RET-IN-18 Inhibitor / 否
HY-146680 FLT3/ITD-IN-4 Inhibitor / 否
HY-153676 RET-IN-23 Inhibitor / 否
HY-144170 RET-IN-14 Inhibitor / 否
HY-149415 Multi-kinase-IN-5 Inhibitor / 否
HY-10981S1 Lenvatinib-d5 Inhibitor / 否
HY-148015 Enbezotinib (enantiomer) Inhibitor 99.72% 否
HY-10981S2 Lenvatinib-15N,d4 Inhibitor / 否
HY-146710 RET-IN-16 Inhibitor / 否
HY-153941 RET-IN-24 Inhibitor / 否
HY-114588 Tafetinib analogue 1 Inhibitor / 否
HY-15769A WHI-P180 hydrochloride Inhibitor / 否
HY-18817 AFG210 Inhibitor / 否
HY-148742 RET-IN-21 Inhibitor 97.00% 否
HY-116116 Tafetinib Inhibitor / 否
HY-149451 SYHA1815 Inhibitor / 否
HY-164549 XMD15-44 Inhibitor / 否
HY-162565 CDD-2807 Inhibitor / 否
HY-164482 HG-6-63-01 Inhibitor / 否
HY-144030 RET-IN-12 Inhibitor / 否
HY-112950 RET-IN-1 Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Ret NCBI NCBI:5979
Canis familiaris Ret NCBI NCBI:403494
Macaca fascicularis Ret NCBI NCBI:102135879
Mus musculus Ret NCBI NCBI:19713
Susscrofa domestica Ret NCBI
Macaca mulatta Ret NCBI NCBI:703466
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z